Clinical Trials Logo

Clinical Trial Summary

This phase II trial studies how well surgery works in preventing ovarian cancer in patients with genetic mutations at risk of ovarian cancer. Risk reducing salpingo oophorectomy (RRSO) is surgery to remove the fallopian tubes and ovaries at the same time. Interval salpingectomy with delayed oophorectomy (ISDO) is surgery to remove the fallopian tubes. It is not known whether ISDO works better than RRSO at lowering risk of ovarian cancer and improving the sexual function and psychosocial well-being in patients with genetic mutation.


Clinical Trial Description

Primary Objectives: 1. To examine changes in female sexual function with the strategy of interval salpingectomy and delayed oophorectomy (ISDO) compared to the strategy of risk-reducing salpingo-oophorectomy (RRSO) for patients who carry genetic mutations that predispose them to ovarian cancer. Secondary Objectives: 1. To estimate the onset and severity of menopausal symptoms with ISDO compared to RRSO. 2. To estimate quality of life with ISDO compared to RRSO. 3. To examine participants' satisfaction level and cancer worry level with their choice of prophylactic procedures. 4. To estimate the impact of ISDO compared to RRSO on mental health, including depression, anxiety, and sleep quality. 5. To determine the compliance with delayed oophorectomy within the ISDO arm. 6. To estimate the number of fallopian tube, ovarian, primary peritoneal malignancies and other malignancies over the course of the study. 7. To identify common themes regarding influential factors in the decision to undergo risk reducing surgery in premenopausal women at genetic high-risk for ovarian can OUTLINE: Patients are assigned to 1 of 2 arms. ARM I: Patients undergo ISDO. ARM II: Patients undergo RRSO. After completion of study treatment, patients are followed up at 1 and 6 months, 1 year, and 2 years. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02760849
Study type Interventional
Source M.D. Anderson Cancer Center
Contact
Status Active, not recruiting
Phase N/A
Start date May 2, 2016
Completion date May 31, 2041

See also
  Status Clinical Trial Phase
Completed NCT00535119 - Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer Phase 1
Recruiting NCT03294343 - Risk-Reducing Surgeries for Hereditary Ovarian Cancer N/A
Completed NCT02956681 - Statewide Communication to Reach Diverse Low Income Women N/A
Completed NCT00305695 - Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries Phase 2
Active, not recruiting NCT03832985 - Pediatric Reporting of Adult-Onset Genomic Results Early Phase 1
Recruiting NCT02653105 - Women at Risk of Breast Cancer and OLFM4 N/A
Completed NCT01367639 - Trial of Inquiry Based Stress Reduction (IBSR) Program for BRCA1/2 Mutation Carriers Phase 2
Completed NCT02562170 - Protexa® Versus TiLoopBra® in Immediate Breast Reconstruction- A Pilot Study Phase 4
Recruiting NCT03162276 - Trial of Inquiry Based Stress Reduction (IBSR) Program for BRCA1/2 Mutation Carriers Phase 3
Not yet recruiting NCT01445275 - Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199 N/A
Recruiting NCT03015376 - Inherited Susceptible Genes Among Epithelial Ovarian Cancer
Enrolling by invitation NCT04197856 - Direct Information to At-risk Relatives N/A
Completed NCT03784859 - Tissue Expansion in Breast Reconstruction Without Drains
Completed NCT04544501 - Enhance the Use of Genetic Counseling and Testing in Latinas N/A
Completed NCT00609505 - Telemedicine vs. Face-to-Face Cancer Genetic Counseling N/A
Terminated NCT02705924 - Impact of a Psychoeducational Intervention on Expectations and Coping in Young Women Exposed to a High HBOC Risk N/A
Completed NCT01333748 - Search Allelic Imbalance of Expression of BRCA Genes in Hereditary Risk of Breast and/or Ovarian Cancer Phase 2
Completed NCT00892736 - Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy Phase 1
Recruiting NCT05677048 - Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention N/A